AMPH: מכפיל P/S Amphastar

Rising Glucagon sales and the launch of new generics are driving shares higher, as confirmed by the price-to-sales valuation on the GURU.Markets system chart, where the value 1.60 describes the current level. A stable staff of analytical chemists and a loyal R&D center support production. High clinical confidence in the quality of injectable systems solidifies the reputation of Amphastar Pharmaceuticals (AMPH) as a reliable brand.

Utilizing external outsourcing for testing and packaging allows Amphastar Pharmaceuticals (AMPH) to flexibly scale sales while optimizing capital expenditures. The price-to-sales ratio trend reflects the market's valuation of this efficiency by comparing the business value to annual revenue; an increase in this multiple signals inflated investor expectations, which raises the risk of a correction should any deviation from the product implementation plan occur.